TY - JOUR
T1 - Clinicopathologic features of brain metastases from gynecologic malignancies
T2 - A retrospective study of 139 cases (KCOG-G1001s trial)
AU - Nasu, Kaei
AU - Satoh, Toyomi
AU - Nishio, Shin
AU - Nagai, Yutaka
AU - Ito, Kimihiko
AU - Otsuki, Takeo
AU - Hongo, Atsushi
AU - Hirashima, Yasuyuki
AU - Ogura, Tomonori
AU - Shimada, Muneaki
PY - 2013/2
Y1 - 2013/2
N2 - Objective: Although brain metastases from gynecologic malignancies are rare, such cases have been gradually increasing in number. The aim of the present study was to evaluate the clinicopathologic features and prognostic factors of brain metastases from gynecologic malignancies. Methods: Retrospective analysis of 139 patients with brain metastases from gynecologic malignancies was carried out as a multi-institutional study. The clinicophathological data of the patients were collected from medical records. Results: Median survival time of the patients with brain metastases was 12.5 months for the ovarian cancer group, 6.2 months for the corpus cancer group, and 5.0 months for the cervical cancer group; two-year overall survival rates were 19.7%, 6.1%, and 4.8%, respectively. Multivariate analysis revealed ovarian/tubal/peritoneal origin, KPS > 70, single brain metastasis, absence of extracranial disease, cranial surgery, cranial radiotherapy, and chemotherapy to be independent favorable prognostic factors associated with overall survival. Conclusion: It is considered that aggressive multimodal therapy is warranted in the treatment of brain metastases from gynecologic malignancies in carefully selected patients. The present study may provide a platform for the discussion of management strategies in these rare clinical scenarios.
AB - Objective: Although brain metastases from gynecologic malignancies are rare, such cases have been gradually increasing in number. The aim of the present study was to evaluate the clinicopathologic features and prognostic factors of brain metastases from gynecologic malignancies. Methods: Retrospective analysis of 139 patients with brain metastases from gynecologic malignancies was carried out as a multi-institutional study. The clinicophathological data of the patients were collected from medical records. Results: Median survival time of the patients with brain metastases was 12.5 months for the ovarian cancer group, 6.2 months for the corpus cancer group, and 5.0 months for the cervical cancer group; two-year overall survival rates were 19.7%, 6.1%, and 4.8%, respectively. Multivariate analysis revealed ovarian/tubal/peritoneal origin, KPS > 70, single brain metastasis, absence of extracranial disease, cranial surgery, cranial radiotherapy, and chemotherapy to be independent favorable prognostic factors associated with overall survival. Conclusion: It is considered that aggressive multimodal therapy is warranted in the treatment of brain metastases from gynecologic malignancies in carefully selected patients. The present study may provide a platform for the discussion of management strategies in these rare clinical scenarios.
KW - Brain metastases
KW - Cervical cancer
KW - Corpus cancer
KW - Ovarian cancer
KW - Prognosis
KW - Radiation
UR - http://www.scopus.com/inward/record.url?scp=84872845432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872845432&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2012.11.001
DO - 10.1016/j.ygyno.2012.11.001
M3 - Article
C2 - 23142074
AN - SCOPUS:84872845432
SN - 0090-8258
VL - 128
SP - 198
EP - 203
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -
